AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug; Company initially believed the drug, emraclidine, could transform the schizophrenia treatment landscape

Saved in:
Bibliographic Details
Published in:The Wall Street journal. Eastern edition 2025-01-10
Main Author: Kellaher, Colin
Format: Newspaper Article
Language:English
Subjects:
Schizophrenia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2574-9579